Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
eciruciclib
- Development stage
- Phase 2
- Lead developer
- Beta Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Eciruciclib (BPI-1178) is an orally bioavailable small molecule inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6). Developed by Beta Pharma, it is designed to arrest the cell cycle in the G1 phase, thereby inhibiting the proliferation of cancer cells. It is currently being investigated in Phase 1/2a clinical trials for the treatment of advanced solid tumors and hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer, both as a monotherapy and in combination with endocrine therapies such as fulvestrant or letrozole.
- Other names
- eciruciclib
02
Targets
CDK4 (Cyclin-dependent kinase 4)CDK6 (Cyclin-dependent kinase 6)
Beyond the preview
Go deeper on eciruciclib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on eciruciclib.